Anzeige
Mehr »
Dienstag, 30.06.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
327 Leser
Artikel bewerten:
(2)

Infinx Healthcare: Infinx Named as a Representative Vendor in Gartner 2026 Market Guide for Intelligent Prior Authorization, U.S. Healthcare Organizations

CUPERTINO, CA / ACCESS Newswire / March 31, 2026 / Infinx Healthcare, a technology-enabled revenue cycle solutions provider, announced today that it was named as a Representative Vendor in the Gartner Market Guide for Intelligent Prior Authorization, U.S. Healthcare Organizations, published Feb. 12, 2026 (ID G00803711).

As per Gartner, "This guide helps CIOs to understand the intelligent prior authorization market, identify vendors and make better-informed purchasing decisions. "

Prior authorization remains one of the most administratively complex processes in healthcare operations and a significant contributor to revenue leakage for healthcare organizations. Increasing payer requirements, evolving documentation standards, and manual workflows can impact turnaround times and operational performance. Healthcare organizations are increasingly exploring automation and AI-enabled workflow technologies to help streamline authorization management and improve transparency across teams.

Jaideep Tandon, CEO of Infinx, said:

"We believe our inclusion in the Gartner Market Guide reflects the growing need for intelligent automation in prior authorization workflows. Healthcare organizations are looking for scalable solutions that combine advanced technology with operational expertise to help manage complexity and support financial performance."

Infinx's Patient Access Plus platform supports prior authorization and related pre-service workflows through configurable work queues, guard railed automation to support determination, initiation, and follow up, and human-in-the-loop coverage that routes exceptions and non automatable work to RCM experts, with oversight and QA built into the workflow. The platform supports multiple integration options including HL7, API, and FHIR connectivity. It also supports payer connectivity through clearinghouses, direct integrations, and payer portal automation where available. In addition to prior authorization, Patient Access Plus supports eligibility and benefits verification, insurance discovery, and financial clearance workflows, providing centralized visibility and operational oversight.

To learn more, visit www.infinx.com or request a demo at www.infinx.com/request-a-demo.

Gartner, Market Guide for Intelligent Prior Authorization, U.S. Healthcare Organizations, Connie Salgy, Roger Benn, Amanda Dall'Occhio, 12 February 2026, ID G00803711.

Gartner is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

About Infinx

Founded in 2012, Infinx delivers technology-led patient access and revenue cycle outcomes for healthcare providers through agentic AI solutions, outsourced operations, and revenue integrity consulting. The company helps improve revenue realization, operational efficiency, and cash acceleration across healthcare administrative workflows. Backed by KKR and Norwest, Infinx is trusted by more than 900 provider organizations across the United States. For more information, visit www.infinx.com.

Infinx media contact:

Stuart Newsome
Infinx
stuart.newsome@infinx.com

SOURCE: Infinx Healthcare



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/infinx-named-as-a-representative-vendor-in-gartnerr-2026-market-guide-1153633

© 2026 ACCESS Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.